SCONE™
Urinary Incontinence due to Neurogenic Bladder (from Spinal Cord Injury, MS, or Stroke)
Phase 2/3Active
Key Facts
Indication
Urinary Incontinence due to Neurogenic Bladder (from Spinal Cord Injury, MS, or Stroke)
Phase
Phase 2/3
Status
Active
Company
About SpineX
SpineX is a private, clinical-stage medical device company pioneering non-invasive spinal cord neuromodulation. Its two core investigational devices, SCONE™ for neurogenic bladder and SCiP™ for cerebral palsy, have both received FDA Breakthrough Device Designation, highlighting their potential to address significant unmet needs. The company is actively recruiting for a global SCONE™ clinical trial and anticipates initiating a pivotal trial for SCiP™ in 2024, targeting a combined market opportunity exceeding $15 billion.
View full company profile